Praxis Precision Medicines, Inc. - 8-K Filing
Praxis Precision Medicines announced on June 1, 2026 that its Phase 2/3 POWER1 study of vormatrigine in patients with focal onset seizures did not meet the primary success measure. However, the secondary endpoint—a 50% response rate—was achieved, and higher doses showed more pronounced seizure reduction; approximately 90% of participants transitioned to an open-label extension study. (Items: 8.01 Other Events)
Tickers: $PRAX